12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD2820: Phase I halted

Palatin said partner AstraZeneca halted a single-blind, placebo-controlled, Phase I trial evaluating AZD2820 in obese men following a serious adverse event in 1 patient. Palatin said the patient may have had an allergic reaction following the first dose, but has fully recovered. The...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >